Market Landscape: The competition in the Global Glucagon-like Peptide 1 (GLP-1) Analogues Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies
RESULTS Liver lesions and biochemistry assessment In controls, the grading system used to microscopically measure the extent of liver damage (the same for steatosis, necrosis, and congestion) showed no lesion presentation at the earliest point of 25 minutes after paracetamol ( Table 1 ), but liver enzymes and ammonium serum values were already increased ( Table 2 )
The peptide is available to patients as a daily subcutaneous injection under the brand names Egrifta and Egrifta SV (SV denoting small volume) [9, 10]
Editors Alvarez-LeefmansF